Lexology July 21, 2025
At-A-Glance
Emerging biotechs and their investors are exploring partnerships with drug companies at a much earlier stage in the company lifecycle, motivated by finding stability in an otherwise volatile and uncertain climate. Our cross-disciplinary team offers considerations for development-stage companies to support a successful major partnership with a pharma company in the following areas.
• Structural Considerations
• IP
• Development and Commercialization
• Regulatory
Early-stage companies thrive on being nimble and running rather than walking. In times when funding is flowing and the initial public offering market is open, entering into a long-term, highly structured arrangement with a large, established company may be one of several options available. But as many emerging biotech companies are realizing today, this type...
Today's Sponsors
Today's Sponsor